SparingVision SAS

https://www.sparingvision.com

LinkedIn: https://linkedin.com/company/sparingvision

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built a compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are a leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology. SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital. *

	Start	2016-06-23 established
	Group	SparingVision (Group)
	Industry	gene therapy eye disease
	Industry 2	SPVN06 mutation-agnostic AAV gene therapy for ofretinitis pigmentosa (SparingVision)
	Person	Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)
	Person 2	Piot, Stanislas (Stentys 201303 CFO)

	Region	Paris
	Country	France
	Street	5/7 avenue Percier CS 40230
	City	75008 Paris
	Tel	+33-1-4346-2060
		Address record changed: 2025-03-04

Basic data	Employees	n. a.

		* Document for »About Section«: SparingVision SAS. (3/3/25). "Press Release: SparingVision Appoints Anjeza Gjino as Chief Financial Officer". Paris.

		Record changed: 2025-03-16